Mackenzie Financial’s Foghorn Therapeutics FHTX Stock Holding History

Mackenzie Financial’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$540K	Buy	+151,354	New	+$797K	﹤0.01%	1307

Other funds holding FHTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $4.69B AUM 22.36% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Mackenzie Financial's FHTX Position: Q3 2026 in Review

Mackenzie Financial opened a new position in Foghorn Therapeutics (FHTX) in Q3 2026: 151,354 shares worth $540K. The stake represents ﹤0.01% of the portfolio and ranks #1307 among its holdings.

33 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

Mackenzie Financial held 151,354 shares of Foghorn Therapeutics worth $540K as of Q3 2026.
Foghorn Therapeutics was a new Mackenzie Financial position in Q3 2026.
Foghorn Therapeutics made up ﹤0.01% of Mackenzie Financial's portfolio in Q3 2026, its #1307 holding.
33 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.